series-b
Stage
About
Sapience Therapeutics is a clinical-stage biotechnology company developing novel peptide therapeutics targeting oncogenic proteins, including CEBP beta and beta-catenin antagonists, with programs in clinical trials for glioblastoma and colorectal cancer.
Explore Sapience Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.